Jun 16, 2014
Astex Pharmaceuticals Presents Final Results of Phase 2 Study of...
DUBLIN, Calif. & CAMBRIDGE, England -- -- Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, presented the final results of a Phase 2 study of SGI-110, a novel hypomethylating agent in elderly Acute Myeloid Leukemia in an oral session on June 14 at the European Hematology ... (more)
Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen from Eisai
Otsuka has acquired rights from Eisai Inc. to develop and sell in the US, Canada and Japan the DNA methylation inhibitor Dacogen A .
Contract Pharma Breaking News
Astex Earns Novartis Milestone
Astex Pharmaceuticals has received a milestone payment from Novartis for the commencement, by Novartis, of a Phase III trial of LEE011, a small-molecule inhibitor of cyclin-dependent kinases 4 and 6 in postmenopausal woman with advanced breast cancer.
KineMed Announces the Hire of Timothy Enns as Chief Investor and Media Relations Officer
KineMed, Inc. announced today that Timothy L. Enns has been hired as Chief Investor and Media Relations Officer.
New Market Research Report: Astex Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report
Astex Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information.